FindTrial
Sign In

A multicenter, random, double-blind, the placebo parallel control trial to evaluate the effectiveness and safety of the hydrochloric acid dexmedetomidine injection in the patients with endotracheal intubation and mechanical ventilation

A multicenter, random, double-blind, the placebo parallel control trial to evaluate the effectiveness and safety of the hydrochloric acid dexmedetomidine injection in the patients with endotracheal intubation and mechanical ventilation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-17011093
Enrollment
Unknown
Registered
2017-04-08
Start date
2017-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

anxiety disorders

Interventions

dexmedetomidine group:dexmedetomidine
control group:saline

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 80 years male or female; (2) the patients need endotracheal intubation and mechanical ventilation, sedation time=6h from random,and light sedation or moderate sedation; (3) the participants or their legal representatives agreed and assigned the informed consent; (4) the pregnancy test is negative for women.

Exclusion criteria

Exclusion criteria: (1) the patients with the central nervous system damage or intracranial surgery; (2) the acute circulatory failure patients with MAP=55mmHg,after active resuscitation by the time of randomization; (3) arrhythmia that might lead to hemodynamic abnormalities;the situations might increase the risk of patients in the opinion of researchers, such as serious bradycardia (HR<50?/min), II-III atrioventricular block(except for pacemaker installation); (4) patients suspected or diagnosis acute coronary syndrome,or the ejection fraction of the left ventricle <30%; (5) unstabled or uncontrolled hyperglycemia; (6) patients who need replacement therapy.

Design outcomes

Primary

MeasureTime frame
the total dose of propofol;—

Countries

China

Contacts

Public ContactJian-guo Li,Zhi-yong Peng

Zhongnan Hospital of Wuhan University

pengzy5@hotmail.com+86 027-67812928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026